News Sentiment

BCYC sentiment intelligence

Bicycle Therapeutics Ltd news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 52 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 4.41 Week of 10 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

79/100 classification confidence.

Company focus 44

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

+1.4% over one week, +8.9% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

ETFs Investing in Bicycle Therapeutics Plc Sponsored ADR Stocks

Market Reaction

Balanced read

62/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 79/100 classification
One-week reaction 1.4% Price digesting
Trend fit Trend inactive 8.9% over four weeks
Fair value -68.7% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 11
Neutral 39
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 44
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 13
Market source 11
TradingView 10
simplywall.st 6
TradingKey 3
Seeking Alpha 2
Investing.com Nigeria 1
Investing.com South Africa 1

Event Lens

What the news is about

Classified themes
Market update 27
Earnings 14
Macro sensitivity 3
Guidance 2
Regulatory and legal 2
Deals and strategy 2
Balance sheet 1
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 52
TradingView Direct company coverage

ETFs Investing in Bicycle Therapeutics Plc Sponsored ADR Stocks

This article lists various ETFs that hold shares of Bicycle Therapeutics Plc Sponsored ADR, providing details such as market value, weight, issuer, expense ratio, and recent performance. The funds are primarily focused on the healthcare and biotechnology sectors, offering investo

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 04:42
Source
TradingView
Stock Titan Direct company coverage

Bicycle Therapeutics (BCYC) CSO executes small RSU tax sell-to-cover trades

Bicycle Therapeutics' Chief Scientific Officer, Michael Skynner, conducted two small "sell-to-cover" transactions to meet tax withholding obligations on vested Restricted Stock Units (RSUs). These sales, occurring on July 2 and July 6, 2026, involved a total of 2,391 Ordinary Sha

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 12:09
Source
Stock Titan
Stock Titan Direct company coverage

Bicycle Therapeutics (BCYC) executive sells shares to cover RSU tax withholding

Bicycle Therapeutics (BCYC) executive Michael Charles Ferguson sold 1,761 Ordinary Shares across two transactions at weighted average prices of approximately $4.27 and $4.31. These sales were not discretionary but mandated "sell to cover" transactions to satisfy statutory tax wit

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 20:40
Source
Stock Titan
Stock Titan Direct company coverage

Bicycle Therapeutics (BCYC) COO sells 1,412 shares in tax-related trades

Bicycle Therapeutics COO Jennifer Scott Perry sold 1,412 Ordinary Shares in tax-related transactions on July 2 and July 6, 2026, at prices between $4.27 and $4.34 per share. These sales were mandated "sell to cover" for statutory tax withholding obligations from RSU vesting, not

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 20:40
Source
Stock Titan
Stock Titan Direct company coverage

Bicycle Therapeutics (BCYC) CFO files sell-to-cover sale of 923 shares

Bicycle Therapeutics CFO Travis Alvin Thompson reported a "sell-to-cover" sale of 923 Ordinary Shares in two open-market transactions. These sales, totaling $3,945, were executed at weighted average prices of $4.27 and $4.31 to fulfill statutory tax withholding obligations on ves

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 20:40
Source
Stock Titan
Stock Titan Direct company coverage

If You Invested $1,000 in Bicycle Therapeutics Limited (BCYC)

This article analyzes the historical performance of investing $1,000 in Bicycle Therapeutics Limited (BCYC) over various periods, showing significant declines over one and five years. It details the company's focus on developing Bicycle® molecules for oncology, including drug con

Tone
Negative 33/100
Event
Market update
Published
04 Jul 2026 23:11
Source
Stock Titan
Stock Titan Direct company coverage

BCYC (Nasdaq: BCYC) files Rule 144 notice listing RSUs and prior sale

Bicycle Therapeutics PLC (BCYC) has filed a Rule 144 notice detailing the proposed sale of common stock and restricted stock units. The filing specifies 12,513 restricted stock units dated July 2, 2026, and 3,594 restricted stock units dated July 3, 2026, alongside a prior sale o

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 19:40
Source
Stock Titan
TradingView Direct company coverage

Price to sales forward of Bicycle Therapeutics plc – NASDAQ:BCYC

This article focuses on the "Price to sales forward" financial metric for Bicycle Therapeutics plc (NASDAQ: BCYC). It appears to be a stub or a data point from a larger financial analysis platform, providing a snapshot of this specific valuation ratio without further narrative. T

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 22:39
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Bicycle Therapeutics plc – NASDAQ:BCYC

The article focuses on the "Price to earnings forward" metric for Bicycle Therapeutics plc (NASDAQ: BCYC). It indicates that the market was closed at the time of publication with no trades having occurred. The page provides general financial information and market data for the co

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 19:41
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Bicycle Therapeutics Plc Sponsored ADR – FWB:50BA

This article displays the "Price to earnings forward" value for Bicycle Therapeutics Plc Sponsored ADR (FWB:50BA) on the Frankfurt Stock Exchange. It provides a financial overview of the company, indicating the market was closed with no trades at the time of viewing. The content

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 18:40
Source
TradingView
TradingView Direct company coverage

Price to book forward of Bicycle Therapeutics plc – NASDAQ:BCYC

This article provides financial information for Bicycle Therapeutics plc (NASDAQ:BCYC), specifically focusing on its "Price to book forward" metric. The content indicates that the market for BCYC was closed at the time of publication, with no trades occurring. The article is part

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 13:40
Source
TradingView
TradingView Direct company coverage

Bicycle Therapeutics Plc Sponsored ADR Actuals & Estimates (NASDAQ:BCYC)

This page provides an overview of Bicycle Therapeutics Plc (NASDAQ:BCYC) financial actuals and analyst estimates. Users can explore reported financial data across income statements, balance sheets, cash flow statements, and valuation metrics, comparing actual results with average

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 12:39
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Bicycle Therapeutics Plc Sponsored ADR – FWB:50BA

This article provides financial data for Bicycle Therapeutics Plc Sponsored ADR (FWB:50BA), specifically focusing on its price-to-sales forward ratio. It highlights the company's financial overview on the Frankfurt Stock Exchange via TradingView, indicating that the market was cl

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 07:41
Source
TradingView
TradingView Direct company coverage

50BA Forecast — Price Target — Prediction for 2027

This article provides the forecast and price target for Bicycle Therapeutics Plc (50BA) trading on the Frankfurt Stock Exchange. It notes a price target of 11.08 based on 9 analysts' 1-year forecasts and mentions that 11 analysts have given stock ratings in the past three months.

Tone
Positive 64/100
Event
Guidance
Published
26 Jun 2026 08:40
Source
TradingView
TradingKey Direct company coverage

Bicycle Therapeutics PLC (BCYC) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Bicycle Therapeutics PLC (BCYC), noting its current valuation score of 7.85 within the Biotechnology & Medical Research industry. It highlights that the company's P/E ratio is -1.25, while data for P/B, P/S, and P/CF ratios are not ye

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 10:11
Source
TradingKey
Investing.com Nigeria Direct company coverage

Bicycle Therapeutics shareholders approve all proposals at annual general meeting

Bicycle Therapeutics plc announced that all proposals presented at its annual general meeting of shareholders were approved. Shareholders re-elected Felix Baker and Hervé Hoppenot as directors, approved executive officer compensation, and ratified the appointments of Pricewaterho

Tone
Positive 71/100
Event
Market update
Published
18 Jun 2026 16:10
Source
Investing.com Nigeria
Investing.com South Africa Direct company coverage

Bicycle Therapeutics shareholders approve all proposals at annual general meeting By Investing.com

Bicycle Therapeutics plc announced that all proposals at its annual general meeting were approved by shareholders. Resolutions included the re-election of Felix Baker and Hervé Hoppenot as directors, advisory approval of executive compensation, and the ratification and re-appoint

Tone
Positive 67/100
Event
Regulatory and legal
Published
18 Jun 2026 13:43
Source
Investing.com South Africa
Stock Titan Direct company coverage

Bicycle Therapeutics (BCYC) AGM approves directors, PwC and pay

Bicycle Therapeutics plc (BCYC) shareholders approved all nine proposals at its Annual General Meeting (AGM) held on June 17, 2026. Key approvals included the re-election of directors Felix Baker and Hervé Hoppenot, advisory approval of executive compensation, and the ratificatio

Tone
Neutral 50/100
Event
Regulatory and legal
Published
18 Jun 2026 12:10
Source
Stock Titan
TradingKey Direct company coverage

Bicycle Therapeutics PLC (BCYC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

The article provides a title for "Bicycle Therapeutics PLC (BCYC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution" but states that relevant data concerning the company's revenue breakdown by business segment and region has not yet been disclosed. It a

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 03:10
Source
TradingKey
TradingKey Direct company coverage

Bicycle Therapeutics PLC (BCYC) Earnings Forecast: Future EPS & Revenue Growth Estimates

Bicycle Therapeutics PLC (BCYC) has an earnings forecast score of 8.00, placing it 163rd in the Biotechnology & Medical Research industry. Analysts have set an average price target of $16.00, with a high of $44.00 and a low of $6.00, primarily recommending a "Buy." The company's

Tone
Positive 72/100
Event
Earnings
Published
17 Jun 2026 12:10
Source
TradingKey
PharmiWeb.com Direct company coverage

Bicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting

Bicycle Therapeutics will present initial data from its randomized Phase 2 Duravelo-2 trial and updated Phase 1 Duravelo-1 trial data at the 2026 ASCO Annual Meeting. The data shows that zelenectide pevedotin (zelenectide) in combination with pembrolizumab achieved encouraging re

Tone
Positive 71/100
Event
Market update
Published
21 May 2026 23:39
Source
PharmiWeb.com
TradingView Direct company coverage

Bicycle Therapeutics presents initial Duravelo-2 data showing comparable ORR and lower toxicity in mUC

Bicycle Therapeutics announced initial Duravelo-2 data for zelenectide in metastatic urothelial cancer, showing comparable response rates and a potentially differentiated safety profile. Data from Duravelo-2 and updated Duravelo-1 trials highlighted high objective response rates

Tone
Positive 73/100
Event
Macro sensitivity
Published
21 May 2026 21:39
Source
TradingView
Stock Titan Direct company coverage

Bladder cancer drug shows 4x fewer skin side effects than standard care

Bicycle Therapeutics announced initial data from its Phase 2 (Duravelo-2) trial and updated data from its Phase 1 (Duravelo-1) trial for zelenectide pevedotin in metastatic urothelial cancer (mUC). The drug, in combination with pembrolizumab, showed comparable response rates to s

Tone
Positive 72/100
Event
Macro sensitivity
Published
21 May 2026 20:39
Source
Stock Titan
Stock Titan Direct company coverage

Duravelo-2 bladder cancer data from Bicycle (NASDAQ: BCYC)

Bicycle Therapeutics (NASDAQ: BCYC) has released initial Duravelo-2 and updated Duravelo-1 clinical data for zelenectide pevedotin in metastatic urothelial cancer. The data indicate response rates and progression-free survival comparable to standard-of-care, alongside a potential

Tone
Positive 67/100
Event
Macro sensitivity
Published
21 May 2026 20:39
Source
Stock Titan
Stock Titan Direct company coverage

Armistice Capital/Steven Boyd disclose 6.75% stake in Bicycle Therapeutics (BCYC)

Armistice Capital, LLC and Steven Boyd have disclosed a 6.75% beneficial ownership stake in Bicycle Therapeutics (BCYC), totaling 3,398,000 American Depositary Shares (ADS) via a SCHEDULE 13G/A SEC filing. Armistice Capital, as the investment manager for a Master Fund, exercises

Tone
Neutral 50/100
Event
Deals and strategy
Published
15 May 2026 15:08
Source
Stock Titan
Stock Titan Direct company coverage

Long Focus Capital (NASDAQ: BCYC) holds 3,310,687 ADS (6.6%)

Long Focus Capital Management, LLC and John Helmers have disclosed beneficial ownership of 3,310,687 American Depositary Shares (ADS) of Bicycle Therapeutics plc (NASDAQ: BCYC), representing 6.6% of the class. This passive investment, reported via a Schedule 13G filing, indicates

Tone
Neutral 50/100
Event
Market update
Published
15 May 2026 13:08
Source
Stock Titan